Prevention of in-stent restenosis via reduction of thrombo-inflammatory reactions with recombinant P-selectin glycoprotein ligand-1

Summary

The binding of leukocyte P-selectin glycoprotein ligand-1 (PSGL-1) to platelet P-selectin is central to post-angioplasty restenosis. Although intracoronary stents limit the mechanical component of restenosis, they cause marked thrombo-inflammation and neointimal proliferation leading to greater late luminal loss. We sought to demonstrate that P-selectin antagonism, using recombinant PSGL-1 (rPSGL-Ig), is effective in reducing platelet-leukocyte reactions and in-stent restenosis in doubleinjured porcine coronary arteries. Two weeks after initial injury by angioplasty to the coronary arteries, stents were implanted at the injury-induced lesion site, 15 min after an IV bolus administration of a vehicle or rPSGL-Ig (1 mg/kg). Four weeks later, adhesion of 51Cr-platelets and 111In-neutrophils and histomorphometric analyses were performed. In-stent residual lumen was almost 3 fold larger in rPSGL-Ig-treated arteries (3.1 ± 0.4 mm2) as compared to control (1.1 ± 0.2 mm2), which correspond to 64% vascular stenosis in control with no change in rPSGL-Ig animals. For a similar injury score, in-stent neointima was significantly reduced by 30 to 40% in the rPSGL-Ig group and quantitative coronary angiography showed a significant 35% reduction in late lumen loss. These effects of rPSGL-Ig were associated with a respective 70% and 53% reduction in platelet and neutrophil adhesion. In conclusion, pretreatment with rPSGL-Ig reduces thrombo-inflammatory responses, neointimal proliferation, and in-stent restenosis. P-selectin antagonism offers a promising therapy to improve clinical outcomes of coronary stenting.

Keywords

Restenosis - stents - leukocytes - platelets - P-selectin - PSGL-1

• References

• 1 Ahmed JM, Mintz GS, Weissman NJ. et al. Mechanism of lumen enlargement during intracoronary stent implantation: an intravascular ultrasound study. Circulation 2000; 102: 7-10.
• 2 Bennett MR, O’Sullivan M. Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy. Pharmacol Ther 2001; 91: 149-66.
• 3 Lowe HC, Oesterle SN, Khachigian LM. Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol 2002; 39: 183-93.
• 4 Merhi Y, Provost P, Chauvet P. et al. Selectin blockade reduces neutrophil interaction with platelets at the site of deep arterial injury by angioplasty in pigs. Arterioscler Thromb Vasc Biol 1999; 19: 372-7.
• 5 McEver RP, Beckstead JH, Moore KL. et al. GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J Clin Invest 1989; 84: 92-9.
• 6 Yang J, Furie BC, Furie B. The biology of P-selectin glycoprotein ligand-1: its role as a selectin counter receptor in leukocyte-endothelial and leukocyte-platelet interaction. Thromb Haemost 1999; 81: 1-7.
• 7 Mickelson JK, Lakkis NM, Villarreal-Levy G. et al. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease?. J Am Coll Cardiol 1996; 28: 345-53.
• 8 Neumann FJ, Ott I, Gawaz M. et al. Neutrophil and platelet activation at ballooninjured coronary artery plaque in patients undergoing angioplasty. J Am Coll Cardiol 1996; 27: 819-24.
• 9 Ott I, Neumann FJ, Gawaz M. et al. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation 1996; 94: 1239-46.
• 10 Wilensky RL, Tanguay JF, Ito S. et al. Heparin infusion prior to stenting (HIPS) trial: final results of a prospective, randomized, controlled trial evaluating the effects of local vascular delivery on intimal hyperplasia. Am Heart J 2000; 139: 1061-70.
• 11 Kutryk MJ, Foley DP, van den Brand M. et al. ITALICS Trial. Local intracoronary administration of antisense oligonucleotide against cmyc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J Am Coll Cardiol 2002; 39: 281-7.
• 12 The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96.
• 13 The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplastycontrolled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Evaluation of platelet IIb/IIIa inhibitor for stenting. Lancet 1998; 352: 87-92.
• 14 Wang K, Zhou Z, Zhou X. et al. Prevention of intimal hyperplasia with recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in the porcine coronary artery balloon injury model. J Am Coll Cardiol 2001; 38: 577-82.
• 15 Kumar A, Villani MP, Patel UK. et al. Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model. Circulation 1999; 99: 1363-9.
• 16 Hayward R, Campbell B, Shin YK. et al. Recombinant soluble P-selectin glycoprotein ligand-1 protects against myocardial ischemic reperfusion injury in cats. Cardiovasc Res 1999; 41: 65-76.
• 17 Wang K, Zhou X, Zhou Z. et al. Recombinant soluble P-selectin glycoprotein ligand-Ig (rPSGL-Ig) attenuates infarct size and myeloperoxidase activity in a canine model of ischemia-reperfusion. Thromb Haemost 2002; 88: 149-54.
• 18 Bienvenu JG, Tanguay JF, Chauvet P. et al. Relationship between platelets and neutrophil adhesion and neointimal growth after repeated arterial wall injury induced by angioplasty in pigs. J Vasc Res 2001; 38: 153-62.
• 19 Bienvenu JG, Tanguay JF, Théorêt JF. et al. Recombinant soluble P-selectin glycoprotein ligand-1-Ig reduces restenosis through inhibition of platelet-neutrophil adhesion after double angioplasty in swine. Circulation 2001; 103: 1128-34.
• 20 Tanguay JF, Hammoud T, Geoffroy P. et al. Chronic platelet and neutrophil adhesion: a causal role for neointimal hyperplasia in instent restenosis. J Endovasc Ther 2003; 10: 968-77.
• 21 Khor SP, McCarthy K, DuPont M. et al. Pharmacokinetics, pharmacodynamics, allometry, and dose selection of rPSGL-Ig for phase I trial. J Pharmacol Exp Ther 2000; 293: 618-24.
• 22 Schwartz RS, Huber KC, Murphy JG. et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 1992; 19: 267-74.
• 23 Chandrasekar B, Tanguay JF. Platelets and restenosis. J Am Coll Cardiol 2000; 35: 555-62.
• 24 Merten M, Thiagarajan P. P-selectin expression on platelets determines size and stability of platelet aggregates. Circulation 2000; 102: 1931-6.
• 25 Caron A, Théorêt JF, Mousa SA. et al. Antiplatelet effects of GPIIb/IIIa and P-selectin antagonism, platelet activation, and binding to neutrophils. J Cardiovasc Pharmacol 2002; 40: 296-306.
• 26 Silverstein RL, Asch AS, Nachman RL. Glycoprotein IV mediates thrombospondindependent platelet-monocyte and platelet- U937 cell adhesion. J Clin Invest 1989; 84: 546-52.
• 27 Spangenberg P, Redlich H, Bergmann I. et al. The platelet glycoprotein IIb/IIIa complex is involved in the adhesion of activated platelets to leukocytes. Thromb Haemost 1993; 70: 514-21.
• 28 Diacovo TG, de Fourgerolles AR, Bainton DF. et al. A functional integrin ligand on the surface of platelets: intercellular adhesion molecule-2. J Clin Invest 1994; 94: 1243-51.
• 29 Bizzaro N, Goldschmeding R, von dem Borne AE. Platelet satellitism is Fc gamma RIII (CD16) receptor-mediated. Am J Clin Pathol 1995; 103: 740-4.
• 30 Simon DI, Chen Z, Xu H. et al. Platelet glycoprotein Ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med 2000; 192: 193-204.
• 31 Santoso S, Sachs UJ, Kroll H. et al. The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J Exp Med 2002; 196: 679-91.
• 32 Evangelista V, Manarini S, Sideri R. et al. Platelet/polymorphonuclear leukocyte interaction: P-selectin triggers protein-tyrosine phosphorylation-dependent CD11b/CD18 adhesion: role of PSGL-1 as a signaling molecule. Blood 1999; 93: 876-85.
• 33 Neumann FJ, Marx N, Gawaz M. et al. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation 1997; 95: 2387-94.
• 34 Bonomini M, Stuard S, Carreno MP. et al. Neutrophil reactive oxygen species production during hemodialysis: role of activated platelet adhesion to neutrophils through P-selectin. Nephron 1997; 75: 402-11.
• 35 Maugeri N, Evangelista V, Celardo A. et al. Polymorphonuclear leukocyte-platelet interaction: role of P-selectin in thromboxane B2 and leukotriene C4 cooperative synthesis. Thromb Haemost 1994; 72: 450-6.
• 36 Inoue T, Uchida T, Yaguchi I. et al. Stentinduced expression and activation of the leukocyte integrin Mac-1 is associated with neointimal thickening and restenosis. Circulation 2003; 107: 1757-63.
• 37 Rogers C, Edelman ER, Simon DI. A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/ CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci USA 1998; 95: 10134-9.
• 38 Simon DI, Dhen Z, Seifert P. et al. Decreased neointimal formation in Mac-1(-/-) mice reveals a role for inflammation in vascular repair after angioplasty. J Clin Invest 2000; 105: 293-300.
• 39 Faraday N, Scharpf RB, Dodd-o JM. et al. Leukocytes can enhance platelet-mediated aggregation and thromboxane release via interaction of P-selectin glycoprotein ligand 1 with P-selectin. Anesthesiology 2001; 94: 145-51.
• 40 Myers D, Wrobleski S, Londy F. et al. New and effective treatment of experimentally induced venous thrombosis with anti-inflammatory rPSGL-Ig. Thromb Haemost 2002; 87: 374-82.
• 41 Lefer AM, Campbell B, Scalia R. et al. Synergism between platelets and neutrophils in provoking cardiac dysfunction after ischemia and reperfusion: role of selectins. Circulation 1998; 98: 1322-8.
• 42 Phillips JW, Barringhaus KG, Sanders JM. et al. Single injection of P-selectin glycoprotein ligand-1 monoclonal antibody blocks neointima formation after arterial injury in apolipoprotein E-deficient mice. Circulation 2003; 107: 2244-9.
• 43 Eppihimer MJ, Schaub RG. P-selectin-dependent inhibition of thrombosis during venous stasis. Arterioscler Thromb Vasc Biol 2000; 20: 2483-8.
• 44 Sarma J, Laan CA, Alam S. et al. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002; 105: 2166-71.
• 45 Théorêt JF, Bienvenu JG, Kumar A. et al. Pselectin antagonism with recombinant p-selectin glycoprotein ligand-1 (rPSGL-Ig) inhibits circulating activated platelet binding to neutrophils induced by damaged arterial surfaces. J Pharmacol Exp Ther 2001; 298: 658-64.
• 46 Libby P, Schwartz D, Brogi E. et al. A cascade model for restenosis. A special case of atherosclerosis progression. Circulation 1992; 86 (suppl III): 47-52.
• 47 Inoue T, Sohma R, Miyazaki T. et al. Comparison of activation process of platelets and neutrophils after coronary stent implantation versus balloon angioplasty for stable angina pectoris. Am J Cardiol 2000; 86: 1057-62.